Loading...
Market
Will Briumvi surpass Ocrevus in market share for MS treatments by 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from industry analysts or financial reports
Story
TG Therapeutics ($TGTX) Reports Positive ENHANCE Phase 3b Data on Briumvi for Multiple Sclerosis
Oct 14, 2024, 11:37 AM
TG Therapeutics ($TGTX) has released new data from its ENHANCE Phase 3b study, showing that rapid 30-minute infusions of Briumvi (ublituximab-xiiy) are well tolerated in patients with relapsing forms of multiple sclerosis. This comes amid comparisons with SubQ Ocrevus, which requires a 10-minute delivery of 23ml of fluid under the skin, potentially causing discomfort and bruising. The total treatment time for SubQ Ocrevus is approximately 1.5 hours, compared to 4.5 hours for IV Ocrevus. KOLS do not favor SubQ Ocrevus, and the Briumvi switching trial is showing promising results.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Yes • 50%
No • 50%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Yes • 50%
No • 50%
